COVID-19 Update: See the latest on our visitor policy here. Learn More
Cancer Type: Multiple
Study Type: Treatment
NCT#: NCT04042701
Phase: Phase I
Principal Investigator: Khong, Hung
A Phase 1b, Multicenter, Two-Part, Open label Study Of Trastuzumab Deruxtecan, An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti PD-1 Antibody, In Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)
This two-part study will include a dose escalation part to determine the recommended dose for expansion of DS8201a and pembrolizumab and a dose expansion part to evaluate efficacy, safety, and tolerability of the combination.
Study Objectives Primary Objectives - To determine the maximum tolerated dose/regimen (MTD) or the recommended dose for expansion (RDE) of DS-8201a when used in combination with pembrolizumab (Part 1) - To evaluate the efficacy of combination treatment with DS-8201a and pembrolizumab in human epidermal growth factor receptor-2 (HER2)-expressing locally advanced/metastatic breast cancer as well as HER2-expressing or HER2- mutant locally advanced/metastatic NSCLC (Part 2) Secondary Objectives - Key Secondary Objectives - To assess the safety and tolerability of the DS-8201a and pembrolizumab regimen - To determine the PK of DS-8201a when dosed in combination with pembrolizumab Other Secondary Objectives Not applicable. Exploratory Objectives - To analyze biomarkers related to the combination treatment - To understand the mechanism of response and resistance based on pretreatment, posttreatment, and on-treatment biopsies
Immunotherapy
DS-8201a (Trastuzumab Deruxtecan); Pembrolizumab (Keytruda); Trastuzumab Deruxtecan ()
Inclusion Criteria:
Exclusion Criteria:
If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.
Back to top
Please call 1-888-663-3488 for support from a Moffitt representative. New Patients and Healthcare Professionals can submit an online form by selecting the appropriate button below. Existing patients can call 1-888-663-3488. Click here for a current list of insurances accepted at Moffitt.
NEW PATIENTS To request a new patient appointment, please fill out the online form or call 1-888-663-3488.
REFERRING PHYSICIANS Providers and medical staff can refer patients by submitting our online referral form.
Moffit now offers Virtual Visits for patients. If you are eligible for a virtual appointment, our scheduling team will discuss this option further with you.
Moffitt Cancer Center is committed to the health and safety of our patients and their families. For more information on how we’re protecting our new and existing patients, visit our COVID-19 Info Hub
Our patient services specialists can assist you with scheduling an appointment, questions about medical records, insurance, billing and more.
Patient Appointment Center Hours: 7 a.m. to 7 p.m. Monday - Friday; 8 a.m. to noon Saturday